Close Menu

research and development

Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.

A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.

The group is developing an ultrasensitive nanoparticle-enhanced plasmonic biosensor to detect RAS single nucleotide variants in plasma.

The funding is part of a BARDA contract worth up to $72 million to support the development of a test to diagnose acute infection at the point of care.

The test detects intact particles by connecting single-stranded DNA with fluorophores to the virus, enabling the detection of a single viral particle.

The company's host-response diagnostics read the immune system using a machine learning algorithm and multiple mRNA biomarkers.

The goal of the project is to build a liquid biopsy-based early detection technology platform and develop tests for lung and digestive system cancers.

The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.

If validation testing goes to plan, the firm believes it can have an inexpensive coronavirus test available for use at the point of care in about six months.

The test was selected for accelerated development and commercialization support by the NIH through the RADx Tech program for COVID-19 diagnostics.

Pages